<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026805</url>
  </required_header>
  <id_info>
    <org_study_id>TMP 200901</org_study_id>
    <nct_id>NCT01026805</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator</brief_title>
  <official_title>Retrospective Case Review - Clinical Evaluation of the Interlace Medical 1st Generation Hysteroscopic Morcellator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hologic, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the effectiveness of intrauterine fibroid and polyp removal using the
      Interlace Medical 1st generation hysteroscopic morcellator device based on a retrospective
      review of medical records of women who have been treated with the device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective review of medical records for eleven (11) premenopausal women who had been
      treated with the new hysteroscopic morcellator was conducted at four hospital or ambulatory
      surgical center sites. Four physicians performed hysteroscopic operative procedures to remove
      intrauterine polyps, type 0 (completely within the uterine cavity), type I (mostly within the
      cavity) and type II (&lt; 40% within the cavity) submucous myomas. Percent pathology removed,
      total morcellation time, total fluid used, fluid deficit and treatment-related adverse events
      were assessed. Each of the four treating physicians also evaluated device performance using a
      10 point scale (1 = &quot;poor&quot; and 10 = &quot;excellent&quot;).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Tissue Removed</measure>
    <time_frame>immediately post-treatment</time_frame>
    <description>mean percentage of polyp and fibroid tissue removed, as measured on post-treatment hysteroscopic imaging. Images were obtained immediately post treatment, before the subject left the surgical suite.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Time Per Patient</measure>
    <time_frame>at time of treatment</time_frame>
    <description>mean morcellation(division into and removal of small pieces, as of tissue) time per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Volume Per Procedure</measure>
    <time_frame>at time of treatment</time_frame>
    <description>mean volume of distension fluid infused into the uterus, per procedure. Distention fluid is used to distend the uterus and provide increased visibility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Deficit Per Procedure</measure>
    <time_frame>at time of treatment</time_frame>
    <description>mean fluid deficit per procedure. Fluid deficit is the difference between the amount of fluid which is infused into the patient during the hysteroscopic procedure, and the amount of fluid collected at completion of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resected Tissue Weight Per Patient</measure>
    <time_frame>at time of treatment</time_frame>
    <description>mean weight of resected tissue per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interlace Medical 1st Generation Hysteroscopic Morcellator Cutting Ability - Mean Score</measure>
    <time_frame>2-3 months post treatment</time_frame>
    <description>a 10 point scale assessed performance of the Interlace Medical 1st Generation Hysteroscopic Morcellator(&quot;1&quot; = &quot;poor&quot; and &quot;10&quot; = &quot;excellent&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2-3 months post-treatment</time_frame>
    <description>Patient medical records were examined to identify any procedure-related or post-treatment adverse events. An adverse event is any undesirable experience (sign, symptom, illness, or other medical event) occurring in a subject, that appears or worsens during a clinical study</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Abnormal Uterine Bleeding</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Hysteroscopic Morcellator</arm_group_label>
    <description>11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interlace Medical 1st Generation Hysteroscopic Morcellator</intervention_name>
    <description>The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.</description>
    <arm_group_label>Hysteroscopic Morcellator</arm_group_label>
    <other_name>MyoSure Tissure Removal System</other_name>
    <other_name>MyoSure Tissure Removal Device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eleven (11) premenopausal women who had been treated with the new hysteroscopic morcellator
        to resect intrauterine pathology (polyps and submucous myomas).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female

          -  at least 18 years old

          -  treated for intra-uterine submucosal fibroids (Type 0 or 1 myomas and/or polyps using
             the Interlace 1st generation morcellator device.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Miller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edward Hospital</affiliation>
  </overall_official>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>April 30, 2009</results_first_submitted>
  <results_first_submitted_qc>November 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2009</results_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>morcellator</keyword>
  <keyword>hysteroscope</keyword>
  <keyword>myomectomy</keyword>
  <keyword>polypectomy</keyword>
  <keyword>uterine fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>An unselected series of eleven (11) premenopausal women who had been treated with the new hysteroscopic morcellator at four hospital or ambulatory surgical center sites were assessed for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hysteroscopic Morcellator Treatment Group</title>
          <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hysteroscopic Morcellator Treatment Group</title>
          <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>size of fibroid or polyp</title>
          <description>measure size of pathology pre-treament via ultrasound or hysteroscopic exam</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.3" lower_limit="5.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Time Per Patient</title>
        <description>mean morcellation(division into and removal of small pieces, as of tissue) time per patient</description>
        <time_frame>at time of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hysteroscopic Morcellator Treatment Group</title>
            <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Time Per Patient</title>
          <description>mean morcellation(division into and removal of small pieces, as of tissue) time per patient</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0.2" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Volume Per Procedure</title>
        <description>mean volume of distension fluid infused into the uterus, per procedure. Distention fluid is used to distend the uterus and provide increased visibility.</description>
        <time_frame>at time of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hysteroscopic Morcellator Treatment Group</title>
            <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Volume Per Procedure</title>
          <description>mean volume of distension fluid infused into the uterus, per procedure. Distention fluid is used to distend the uterus and provide increased visibility.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5179.0" lower_limit="600" upper_limit="24000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Deficit Per Procedure</title>
        <description>mean fluid deficit per procedure. Fluid deficit is the difference between the amount of fluid which is infused into the patient during the hysteroscopic procedure, and the amount of fluid collected at completion of the procedure.</description>
        <time_frame>at time of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hysteroscopic Morcellator Treatment Group</title>
            <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Deficit Per Procedure</title>
          <description>mean fluid deficit per procedure. Fluid deficit is the difference between the amount of fluid which is infused into the patient during the hysteroscopic procedure, and the amount of fluid collected at completion of the procedure.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567.8" lower_limit="30" upper_limit="1900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resected Tissue Weight Per Patient</title>
        <description>mean weight of resected tissue per patient</description>
        <time_frame>at time of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hysteroscopic Morcellator Treatment Group</title>
            <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
          </group>
        </group_list>
        <measure>
          <title>Resected Tissue Weight Per Patient</title>
          <description>mean weight of resected tissue per patient</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="0.5" upper_limit="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interlace Medical 1st Generation Hysteroscopic Morcellator Cutting Ability - Mean Score</title>
        <description>a 10 point scale assessed performance of the Interlace Medical 1st Generation Hysteroscopic Morcellator(“1” = “poor” and “10” = “excellent”).</description>
        <time_frame>2-3 months post treatment</time_frame>
        <population>All treating physicians completed a survey questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Hysteroscopic Morcellator Treatment Group</title>
            <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
          </group>
        </group_list>
        <measure>
          <title>Interlace Medical 1st Generation Hysteroscopic Morcellator Cutting Ability - Mean Score</title>
          <description>a 10 point scale assessed performance of the Interlace Medical 1st Generation Hysteroscopic Morcellator(“1” = “poor” and “10” = “excellent”).</description>
          <population>All treating physicians completed a survey questionnaire.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Patient medical records were examined to identify any procedure-related or post-treatment adverse events. An adverse event is any undesirable experience (sign, symptom, illness, or other medical event) occurring in a subject, that appears or worsens during a clinical study</description>
        <time_frame>2-3 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hysteroscopic Morcellator Treatment Group</title>
            <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Patient medical records were examined to identify any procedure-related or post-treatment adverse events. An adverse event is any undesirable experience (sign, symptom, illness, or other medical event) occurring in a subject, that appears or worsens during a clinical study</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Tissue Removed</title>
        <description>mean percentage of polyp and fibroid tissue removed, as measured on post-treatment hysteroscopic imaging. Images were obtained immediately post treatment, before the subject left the surgical suite.</description>
        <time_frame>immediately post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hysteroscopic Morcellator Treatment Group</title>
            <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Tissue Removed</title>
          <description>mean percentage of polyp and fibroid tissue removed, as measured on post-treatment hysteroscopic imaging. Images were obtained immediately post treatment, before the subject left the surgical suite.</description>
          <units>Percentage of tissue removed</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="50" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hysteroscopic Morcellator Treatment Group</title>
          <description>Subjects underwent hysteroscopic tissue removal of intrauterine polyps and/or myomas using the Interlace Medical tissue removal device.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of cases; retrospective study design</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John Vozella, V.P. Clinical &amp; Regulatory Affairs</name_or_title>
      <organization>Interlace Medical, Inc.</organization>
      <phone>508-875-1343 ext 112</phone>
      <email>john@interlacemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

